Current role
Hetal Kocinsky
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Hetal Kocinsky
Jade Biosciences, Inc. reported in an 8-K filed September 9, 2025 that Hetal Kocinsky resigned as Chief Medical Officer, effective September 9, 2025. Jade Biosciences, Inc. reported in an 8-K filed May 1, 2025 that Hetal Kocinsky was appointed the Company's Chief Medical Officer, effective April 28, 2025.
“Effective September 9, 2025, Hetal Kocinsky, M.D. departed from her position as Chief Medical Officer of Jade Biosciences, Inc. (the "Company").”
“On April 28, 2025, the Board appointed Tom Frohlich as the Company's Chief Executive Officer, Jonathan Quick as the Company's Senior Vice President, Finance and Treasurer, Andrew King as the Company's Chief Scientific Officer & Head of Research and Development, Hetal Kocinsky as the Company's Chief Medical Officer and Elizabeth Balta as General Counsel and Corporate Secretary, each to serve at the discretion of the Board.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Jade Biosciences, Inc. (JBIO)
SEC 8-K
Current2025-04-28–present
-
Jade Biosciences, Inc. (JBIO)
SEC 8-K
2025-04-28–2025-09-09
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Jade Biosciences, Inc.
Other people whose current roles at this company are on record from its filings.
- Tom Frohlich CEO, Board Member
- Eric Dobmeier Chairman, Board Member
- Bradford Dahms CFO
- Benjamin T. Dake COO
- Andrew King CTO
- Elizabeth Balta General Counsel
- Christopher Cain Board Member
- Continuing Directors Board Member
- Donald J. Santel Board Member
- Erin Lavelle Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.